{"id":"NCT01898923","sponsor":"Oneness Biotech Co., Ltd.","briefTitle":"Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers","officialTitle":"Randomized Controlled Study to Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-23","primaryCompletion":"2020-05-11","completion":"2020-05-11","firstPosted":"2013-07-15","resultsPosted":"2021-04-14","lastUpdate":"2021-04-14"},"enrollment":236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Foot"],"interventions":[{"type":"DRUG","name":"ON101 Cream","otherNames":["WH-1"]},{"type":"OTHER","name":"Aquacel® Hydrofiber® dressing","otherNames":[]}],"arms":[{"label":"ON101 Cream","type":"EXPERIMENTAL"},{"label":"Aquacel® Hydrofiber® dressing","type":"OTHER"}],"summary":"The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1 ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers for up to 16 weeks.An additional objective of this study is to collect safety information including adverse events and clinical laboratory abnormalities.","primaryOutcome":{"measure":"Number of Participants With Complete Ulcer Closure","timeFrame":"16 weeks","effectByArm":[{"arm":"ON101 Cream","deltaMin":74,"sd":null},{"arm":"Aquacel® Hydrofiber® Dressing","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":21,"countries":["United States","China","Taiwan"]},"refs":{"pmids":["34477854"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":122},"commonTop":["Hyperuricaemia","Eczema","Peripheral swelling","Pyrexia","Cellulitis"]}}